お知らせ • Jun 24
Revium Rx. Announces Resignation of Inna Martin from Director, Chief Operating Officer and President, Effective June 16, 2026 Revium Rx. announced that on June 16, 2026, Ms. Inna Martin resigned from her position as a member of the Board of Directors of Revium Rx. and as Chief Operating Officer and President thereof, effective immediately. Ms. Martin's resignation was in light of certain differences in expectations between her and the Company. At the time of her resignation, Ms. Martin did not hold positions on any committees of the Board of Directors. In connection with Ms. Martin's departure, the Company's subsidiary, Revium Rx Ltd. and Ms. Martin entered into a Termination Agreement and Waiver (the Separation Agreement), effective as of June 16, 2026, pursuant to which Ms. Martin's employment and consultancy engagement with Revium Ltd. will terminate on September 10, 2026. Ms. Martin's shares and options are subject to certain sale restrictions as contained in the Separation Agreement. お知らせ • Oct 22
Revium Recovery Inc. Advances Toward Phase 1 Clinical Development of Nano-Mupirocin to Combat Antibiotic-Resistant Infections Revium Rx announced significant progress in its regulatory and manufacturing programs supporting the planned Phase 1 clinical trial of its lead product candidate, Nano-Mupirocin - a novel systemic formulation of the well-known and highly potent antibiotic mupirocin. Last month, the company submitted its clinical trial application to the Israeli Ministry of Health, marking a critical milestone toward the initiation of first-in-human studies in early 2026. Concurrently, Revium Rx, in collaboration with WuXi AppTec, one of the world's leading global CDMOs, continues to advance the scale-up and production of its GMP clinical batch, with final release expected by the end of 2025. Addressing the Urgent Threat of Antimicrobial Resistance (AMR) In 2021, Methicillin-Resistant Staphylococcus Aureus (MRSA) was estimated to have caused approximately 130,000 deaths directly attributable to antimicrobial resistance (AMR) -- a sharp rise from 57,200 in 1990. According to the Global Research on Antimicrobial Resistance (GRAM) Project published in The Lancet in 2022, MRSA was responsible for over 100,000 AMR-attributable deaths in 2019, making it one of the deadliest pathogens that year. The global AMR therapeutics market was valued at USD 8.7 billion in 2023 and is projected to exceed USD 12.5 billion by 2030, growing at a CAGR of 5.3 %, according to Grand View Research, 2024. Within this rapidly expanding global market, Nano-Mupiroci targets several high-value infectious disease indications, including Methicillin-ResistantStaphylococcus aureus (MRSA), Vancomycin-Resistant Enterococci (VRE), and Ceftriaxone-Resistant Gonorrhea (CR-Gonorrhea). If Nano-Mupirocin demonstrates favorable results in clinical trials, of which no assurance can be provided, the Company will seek to capture a meaningful share within this rapidly expanding market, reflecting both the urgent clinical need and the significant commercial potential of novel antibiotics effective against resistant pathogens. お知らせ • Feb 14
Revium Recovery Inc. has filed an IPO in the amount of $5 million. Revium Recovery Inc. has filed an IPO in the amount of $5 million.
Security Name: Units
Security Type: Equity/Derivative Unit
Securities Offered: 1,562,500
Price\Range: $3.2
Discount Per Security: $0 お知らせ • Feb 06
Revium Recovery Inc. (OTCPK:RVRC) completed the acquisition of LipoVac, Ltd. Revium Recovery Inc. (OTCPK:RVRC) entered into a letter of intent to acquire LipoVac, Ltd. on December 20, 2022. Revium Recovery will issue shares in exchange for all of LipoVac’s outstanding capital stock. The transaction is subject to satisfactory due diligence by the parties and the entry into a definitive merger agreement. The transaction is also subject to Revium completing a private placement of its securities with net proceeds to Revium of at least $7 million.
Revium Recovery Inc. (OTCPK:RVRC) completed the acquisition of LipoVac, Ltd. on February 4, 2025. お知らせ • Dec 22
Revium Recovery Inc. (OTCPK:RVRC) entered into a letter of intent to acquire LipoVac, Ltd. Revium Recovery Inc. (OTCPK:RVRC) entered into a letter of intent to acquire LipoVac, Ltd. on December 20, 2022. Revium Recovery will issue shares in exchange for all of LipoVac’s outstanding capital stock. The transaction is subject to satisfactory due diligence by the parties and the entry into a definitive merger agreement. The transaction is also subject to Revium completing a private placement of its securities with net proceeds to Revium of at least $7 million.